Ustekinumab for the treatment of psoriasis

Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor α biologics and switched to ustekinumab

(2010) A.M.R. Downs   BRITISH JOURNAL OF DERMATOLOGY

Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre

(2010) R.B. Warren et al.   BRITISH JOURNAL OF DERMATOLOGY

Ustekinumab in the treatment of palmoplantar pustulosis

(2010) S. Gerdes et al.   BRITISH JOURNAL OF DERMATOLOGY

Treatment of pityriasis rubra pilaris with ustekinumab

(2010) J. Wohlrab et al.   BRITISH JOURNAL OF DERMATOLOGY

Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial

(2010) Arthur Kavanaugh et al.   CURRENT MEDICAL RESEARCH AND OPINION

The use of ustekinumab in autoimmune disease

(2010) Caitriona Ryan et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters

(2010) Manjula REDDY et al.   JOURNAL OF DERMATOLOGY

Oesophageal squamous cell carcinoma in a young adult with IL-12R 1 deficiency

(2010) M. Cardenes et al.   JOURNAL OF MEDICAL GENETICS

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial

(2010) Richard G. Langley et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations

(2010) Mark Lebwohl et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

(2010) Christopher E.M. Griffiths et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms

(2009) R.B. Warren et al.   BRITISH JOURNAL OF DERMATOLOGY

British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009

(2009) C.H. Smith et al.   BRITISH JOURNAL OF DERMATOLOGY

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial

(2009) M. Lebwohl et al.   BRITISH JOURNAL OF DERMATOLOGY

Ustekinumab

(2009) Anna L. Chien et al.   DRUGS

Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-α/β, IFN-γ, and IFN-λ in host defense

(2009) Shen-Ying Zhang et al.   IMMUNOLOGICAL REVIEWS

Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes

(2009) Lisa C. Zaba et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis

(2009) Yaowei Zhu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis

(2009) Mary G. Boy et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

(2009) Alice Gottlieb et al.   LANCET

Psoriasis

(2009) Frank O. Nestle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre

(2008) R.B. Warren et al.   BRITISH JOURNAL OF DERMATOLOGY

Long-term control of recalcitrant psoriasis with combination infliximab and methotrexate

(2008) R. B. Warren et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Novel primary immunodeficiencies revealed by the investigation of paediatric infectious diseases

(2008) Jacinta Bustamante et al.   CURRENT OPINION IN IMMUNOLOGY

No Association between Polymorphisms in the Interleukin-15 Gene and Early-Onset Psoriasis in a UK Cohort Suggests Heterogeneity for this Susceptibility Locus Identified in Chinese Psoriasis Patients

(2008) Rhodri Ll Smith et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Genetic Variation in Efflux Transporters Influences Outcome to Methotrexate Therapy in Patients with Psoriasis

(2008) Richard B. Warren et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents

(2008) Sean D. Doherty et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

(2008) Benjamin M Segal et al.   LANCET NEUROLOGY

From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis

(2007) Mark Lebwohl et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY